Published Paper Details:

Background: The corona virus disease 2019(COVID-19) pandemic (officially declared on the March 11, 2020), and the resulting measures, are impacting daily life and medical management of cancer patients. This study is intended to evaluate the association between COVID 19 pandemic and cancer survival, and to explore the prevalence of co-morbidities in cancer patients. Methods and materials used: The retrospective study was carried out in the oncology department for a period of six months. The data were collected from patient history and, Medical Record Department. A total of 150 subjects were included in this study with 75 Pre-pandemic cancer patients and similar age , gender matched 75 Post- pandemic patients . Charlson Comorbidity Index (CCI) is used to assess the survival rate of cancer patients. Results: Based on the comparison of survival rate of Pre-pandemic and Post-pandemic cancer patients, the Pre-pandemic cancer patients have mild survival rate (44%) and the Post-pandemic cancer patients have moderate survival rate (62.67%). Both males and females among the study population have moderate survival rate of 44.12% and 51.22% respectively. By comparing the survival rate of breast cancer patients with other cancer patients, both the groups have moderate risks of survival for next 10 years (46.34%) and (48.62%) respectively. Metastatic cancer patients have severe risks of survival (59.02%), whereas other cancer patients have moderate risks of survival (100%) for the next 10 years. Conclusion: The prevalence of co-morbidities in cancer patients has increased after the covid-19 pandemic. Our finding reveals that the risk of survival of cancer patients has increased from mild to moderate level after covid-19 pandemic.